With the advent of third-generation TKIs, the landscape has shifted, endorsed by the phase III MARIPOSA-2 study in which in EGFR-mutant advanced NSCLC following osimertinib resistance,412 amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy can improve the median intracranial PFS, compared to chemotherapy alone, while no statistically significant difference in OS was reported in the preliminary analysis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.